Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CEO Eric Lefkofsky sold 166,250 shares of the stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $51.13, for a total value of $8,500,362.50. Following the sale, the chief executive officer owned 8,841,783 shares in the company, valued at approximately $452,080,364.79. This represents a 1.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Tempus AI Stock Performance
Shares of TEM opened at $55.48 on Friday. The business's fifty day simple moving average is $50.65 and its two-hundred day simple moving average is $63.58. The company has a current ratio of 3.13, a quick ratio of 3.00 and a debt-to-equity ratio of 2.52. Tempus AI, Inc. has a 12 month low of $41.73 and a 12 month high of $104.32. The company has a market cap of $9.92 billion, a price-to-earnings ratio of -39.35 and a beta of 4.90.
Wall Street Analysts Forecast Growth
TEM has been the topic of several recent analyst reports. Wall Street Zen downgraded Tempus AI from a "hold" rating to a "sell" rating in a research note on Saturday, February 28th. TD Cowen upgraded Tempus AI from a "hold" rating to a "buy" rating and set a $65.00 target price on the stock in a research note on Monday, April 13th. HC Wainwright raised their price target on Tempus AI from $89.00 to $95.00 and gave the stock a "buy" rating in a research note on Monday, March 9th. Mizuho began coverage on Tempus AI in a research note on Thursday, February 19th. They issued an "outperform" rating and a $100.00 price target on the stock. Finally, Jefferies Financial Group began coverage on Tempus AI in a research note on Monday, April 13th. They issued an "underperform" rating and a $35.00 price target on the stock. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $71.36.
Check Out Our Latest Report on TEM
Hedge Funds Weigh In On Tempus AI
Institutional investors and hedge funds have recently modified their holdings of the company. JPL Wealth Management LLC purchased a new position in shares of Tempus AI in the 3rd quarter worth $26,000. Los Angeles Capital Management LLC purchased a new position in shares of Tempus AI in the 4th quarter worth $27,000. Harvest Fund Management Co. Ltd purchased a new position in shares of Tempus AI in the 3rd quarter worth $38,000. Tsfg LLC boosted its stake in shares of Tempus AI by 1,515.2% in the 3rd quarter. Tsfg LLC now owns 533 shares of the company's stock worth $43,000 after buying an additional 500 shares during the last quarter. Finally, Cloud Capital Management LLC purchased a new position in shares of Tempus AI in the 3rd quarter worth $44,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.
Tempus AI News Summary
Here are the key news stories impacting Tempus AI this week:
- Positive Sentiment: Company set its inaugural Investor Day for May 29, 2026 — management will present strategy, product road map and commercialization plans, which can increase visibility and reduce short-term uncertainty around growth targets. Tempus to Host Inaugural Investor Day on May 29, 2026
- Positive Sentiment: Brand and partnership momentum: Tempus was named to TIME’s 10 Most Influential Health & Life Science Companies of 2026 and announced a multi‑year collaboration with USC/Keck, boosting the company’s credibility in AI-driven precision medicine and supporting longer-term commercial adoption. Tempus AI’s TIME Honor And USC Deal Test Its Long Term Thesis
- Positive Sentiment: Bull case coverage surfaced (Gannon Capital summary) highlighting long‑term upside drivers and growth potential, which may attract momentum buyers and retail interest. Is Tempus AI, Inc. (TEM) A Good Stock To Buy Now?
- Neutral Sentiment: CEO Eric Lefkofsky sold 166,250 shares under a pre‑arranged Rule 10b5‑1 plan (disclosed filing). Such planned insider sales often serve liquidity/personal reasons but can still be interpreted variably by the market. SEC Form 4 disclosure
- Neutral Sentiment: Analyst/valuation notes show mixed views: small tweak to blended fair value and writeups assessing a short-term bounce versus longer-term declines — suggesting investors are debating whether recent gains are sustainable. How The Tempus AI (TEM) Narrative Is Shifting Around Data, Partnerships And Growth Visibility
- Negative Sentiment: Tempus faces proposed class action litigation related to collection of genetic information in an acquisition — legal exposure and potential remediation costs create downside risk and uncertainty that can pressure sentiment and valuation. Tempus AI Faces Class Action Cases for Collection of Genetic Information in Acquisition
- Negative Sentiment: Peer comparison pieces favor Illumina (ILMN) on valuation and earnings outlook, which could steer institutional allocation away from TEM if investors view ILMN as the better pure‑play oncology/ genomics investment. Tempus AI vs. Illumina: Which Oncology Stock Is Worth Buying Now?
Tempus AI Company Profile
(
Get Free Report)
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
